Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers

Maureen Bernadach¹,²,³, Michel Lapeyre⁴, Anne-Françoise Dillies¹, Jessica Miroir⁴, Melanie Casile²,³,⁵, Juliette Moreau⁴, Ioana Molnar²,³,⁵, Angeline Ginzac²,³,⁵, Nathalie Pham-Dang⁶, Nicolas Saroul⁷, Xavier Durando¹,²,³,⁵ and Julian Biau⁴,⁵

Abstract

Background: The rate of toxic deaths related to induction chemotherapy in the treatment of locally advanced head and neck cancers is unacceptable and calls into question this therapeutic strategy, which is however highly effective in terms of rate and speed of response. The purpose of the study was to investigate predictive factors of toxicity of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced head and neck cancers (LAHNC).

Methods: Between June 2009 and December 2017, 113 patients treated consecutively with TPF were included retrospectively. Patients were receiving induction chemotherapy for either an inoperable cancer or laryngeal preservation. For inoperable cancer, induction chemotherapy was proposed to patients presenting either a large tumor with strong symptoms (dyspnea, dysphagia, pain) or a tumor with rapid progression. Risk factors were chosen among the initial patient and tumour characteristics and chemotherapy modalities.

Results: Eighty-nine patients (79%) were male; the median age was 58 years [32–71]. Sixty-nine (61%) patients were treated for inoperable cancer and 44 (39%) for laryngeal preservation. 45% had stage IVa cancer, 28% stage III and 25% stage IVb. Sixty percent of patients had a partial response after TPF, 22% had a complete response, 12% were stable, 5% were progressing, and 1% had a discordant response. Thirty-four patients (30%) received enteral feeding during induction chemotherapy with TPF. The possibility of oral feeding without a tube was predictive of a better response (p = 0.003). Seven (6%) patients died during TPF. There was an increased risk of death with preexisting liver dysfunction (liver dysmorphia on imaging or decrease prothrombin rate) (p = 0.032). There was an increased risk of grade ≥ 3 infection if an enteral feeding occurred during the period of induction chemotherapy (p = 0.03).

Conclusions: TPF induction chemotherapy had an 82% objective response rate with 6% toxic deaths. Nutritional status and the presence of hepatic dysfunction are significant risk factors to be taken into account in therapeutic decisions.

Keywords: Head and neck cancer, Induction chemotherapy, TPF, Toxicity, Nutritional status, Hepatic dysfunction
Background
Sixty percent of head and neck squamous cell carcinomas (HNSCC) are diagnosed at locally advanced stages [1]. Until the early 1990s, local treatments (surgery and/or radiotherapy [RT]) were the key components of treatment for locally advanced head and neck cancers (LAHNC) [2, 3] with a high rates of relapse and morbidity [4, 5]. To improve cure rates and functional outcomes, chemotherapy has been integrated into various strategies (concurrent radiochemotherapy, induction chemotherapy and a combination of both) [6–13]. These strategies have been applied in patients with non-operable cancers [6–11, 14] and in patients with resectable disease who are candidates for organ preservation [9, 12, 13, 15–17].

Induction chemotherapy combining cisplatin-5-fluorouracil (PF) followed by RT was initially approved for organ preservation in locally advanced, operable laryngeal squamous cell carcinomas (SCC) requiring total laryngectomy [17, 18]. In 2006, the GORTEC 2000–01 [19] trial demonstrated the superiority of the docetaxel-cisplatin-5-fluorouracil (TPF) combination to the PF induction regimen in the management of these laryngeal SCC eligible for an organ preservation strategy. For inoperable LAHNSCC, a large meta-analysis [11] compared TPF to PF induction, also showing TPF’s superiority. Thus, TPF induction chemotherapy, already used in laryngeal preservation strategies, has been extended to all inoperable LAHNSCC with large tumour (T3 - T4) or lymph node extension (N2c - N3) with high risk of micro-metastases, without any formal proof of its superiority or non-inferiority compared to the standard treatment of concomitant radiochemotherapy.

The exact place of TPF induction chemotherapy for LAHNSCC over standard concomitant radiochemotherapy [10] has been questioned by several studies [20–25]. The National Comprehensive Cancer Network (NCCN) guidelines include induction chemotherapy with TPF followed by RT alone or by radiochemotherapy [26] as a validated treatment option. Indeed, TPF induction chemotherapy continues to be used due to a high response rate and an unequalled rapidity of response, often allowing a rapid regression of severe symptomatology (dyspnea, dysphagia, pain...).

However, TPF induction chemotherapy introduces a high risk of severe toxicities. These toxicities, in patients with many co-morbidities, can be fatal, with death rates ranging from 0 to 6.7% [8, 20–23, 27]. In addition, 20–30% of patients starting induction chemotherapy do not receive all of the radiotherapy +/- concomitant chemotherapy [8, 28, 29]. Thus, this treatment strategy may show better outcomes in better-selected patients with a lower risk of toxicity and better chances of receiving the full course of treatment [21–23, 25, 30, 31]. For now, there are no consensus criteria for selecting these patients. The main aim of this study was to identify predictive factors of toxicity of docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally advanced head and neck cancers (LAHNC), in order to better select patients likely to benefit from this treatment.

Methods
Inclusion population and study endpoints
Between June 2009 and December 2017, 113 patients treated consecutively in our institution with TPF induction chemotherapy were analyzed retrospectively. Patients were receiving induction chemotherapy for either an inoperable cancer or laryngeal preservation. For inoperable cancer, induction chemotherapy was proposed to patients presenting either a large tumor with strong symptoms (dyspnea, dysphagia, pain) or a tumor with rapid progression.

According the French legislation, the database has been declared to the French National Commission on Informatics and Liberty. All patients have been informed about the research by a non-opposition letter. They were free to oppose to the used of their personal data for this study. Study ethics approval was obtained on 18 November 2020 (CECIC Rhône-Alpes-Auvergne, Grenoble, IRB 5921).

The primary endpoint of this study was to identify predictive factor of grade ≥ 3 toxicities of TPF induction chemotherapy. Secondary endpoints included the search of predictive factors of treatment-related deaths, predictive factors of overall response rates and overall survival.

TPF induction chemotherapy
The induction chemotherapy regimen combined docetaxel 75 mg/m² on D1, cisplatin 75 mg/m² on D1 or cisplatin 20 mg/m² from D1 to D4, and 5-fluorouracil 750 mg/m² as a continuous infusion from D1 to D5 every 21 days. Intravenous hydration of 2 to 3 L was administered depending on whether patients were receiving single-dose or fractionated cisplatin. The antiemetic protocol combined aprepitant, corticosteroids, ondansetron and anti-D2. All patients received systematic GCSF as primary prophylaxis in accordance with international recommendations [32]. Premedication with methylprednisolone 50 mg twice daily was given the day before, the day of and the day after docetaxel in order to prevent hypersensitivity reactions, cutaneous adverse reactions and retention syndromes. Systematic dihydropyrimidine dehydrogenase (DPD) deficiency screening was not realized in the study period. According to local recommendations, systematic ciprofloxacine as primary prophylaxis was not realized.
Treatment following TPF induction chemotherapy

Radiotherapy delivered curative doses on the initial tumor/tumor bed of 60 and 66 Gy for operated patients and 70 Gy for non-operated patients, in fractions of 2 Gy to 2.12 Gy through conformal technique or volumetric modulated arc therapy (VMAT). RT was administered alone or concurrently with chemotherapy, which consisted of carboplatin AUC 1.5/week for 7 weeks or cisplatin 40 mg/m²/week for 7 weeks or cisplatin 100 mg/m² W1, W4, W7 or cetuximab 400 mg/m² at D-8 and 250 mg/m²/week for 7 weeks.

Patient follow-up

Acute hematologic and non-hematologic adverse events occurring during induction chemotherapy or radiotherapy were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Responses obtained after TPF and two to three months after the end of radiation therapy were also reported. Tumour response was evaluated clinically by nasofibroscopy and/or CT imaging according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Patients’ responses included complete and partial response, and treatment failure included patients with progression or no response (stable disease) in order to increase the power of the analyses.

Statistical analysis

Statistical analyses were performed using R software (v. 3.5.1, R-Project, GNU GPL [33]). The normality of the continuous variables was tested using a Shapiro-Wilk test. For the statistical hypothesis testing, the α risk was fixed to 5%. Initial patient and tumour characteristics and chemotherapy modalities were analyzed in search of predictive factors of toxicity, death, progression-free survival (PFS) and overall survival (OS). Risk factors of toxicity studied were age, gender, alcohol consumption, presence of hepatic dysmorphia, prothrombin level, diabetes, high blood pressure, history of ischemic heart disease, chronic obstructive bronchitis, oblitative arterial disease of the lower limbs, performance status, weight loss before and during induction chemotherapy and receiving enteral feeding during induction chemotherapy indication for laryngeal preservation or inoperable disease and stage of disease.

The methods used were Fisher’s exact test (for the relationship between pairs of categorical variables), the Wilcoxon-Mann-Whitney test (in case of a continuous and a categorical variable), and a Cox model (for time-to-event data). Statistical significance in the Cox model was assessed using the Wald statistic. Multivariate Cox models were fit using a variable selection method based on a LASSO-type penalized regression using all factors with a p-value < 0.1 in the univariate analysis.

Survival was defined as the time between diagnosis and death, regardless of cause, and living patients had their conditions at the date of the last follow-up statistically censored. Event-free survival was calculated as the time from the date of diagnosis to the date of progression (local, regional, or distant) or death, with patients’ conditions at the last follow-up being censored if no event had occurred. Kaplan-Meier estimates were used for survival rate evaluation, and comparison between survival curves was based on the logrank test.

Results

Characteristics of the population

Sixty-nine (61%) had inoperable LAHNC and 44 (39%) were treated in a laryngeal preservation strategy. The patient and tumor characteristics are summarized in Table 1 and Table 2. The median age was 58 years [32–71], 96% of patients had a World Health Organization (WHO) performance status of 0 or 1. 70% of patients had a history of alcohol and tobacco intoxication. The most frequent tumor sites were the larynx (27%). 92% of cancers were SCC, 7% undifferentiated carcinoma and 1% adenocarcinoma. All tumors were locally advanced with 45% of them classified as stage IVa, 28% stage III and 25% stage IVb. In inoperable tumors, there were one stage II (1%), 9 stage III (13%), 33 stage IVa (48%) and 26 stage IVb (38%). In laryngeal preservation, there were one stage II (2%), 23 stage III (52%), 18 stage IVa (41%) and 2 stage IVb (5%).

The median weight loss at diagnosis was 4.1 kg. 50% of patients experienced stable weight, 23% weight loss between 5 and 10% from baseline, 19% between 10 and 20 and 8% ≥20%. The median serum albumin level was 39.6 g/L (95% CI [37.6–39.8]). Thirty-four patients (30%) had a feeding tube due to initial weight loss.

TPF induction chemotherapy and treatment following TPF

88% of patients received TPF induction chemotherapy with single-dose cisplatin on D1 and 12% received fractionated cisplatin 20 mg/m² from D1 to D4 from the first treatment. The data concerning TPF induction chemotherapy are presented in Table 3. Sixty-four patients (57%) received the full course of TPF induction chemotherapy as originally planned (without cancellation or dose reduction).

The modalities of treatment following TPF induction chemotherapy are presented in Table 3. The median time from the last chemotherapy treatment to the start of radiotherapy was 36 days [24–107] for inoperable LAHNC and for laryngeal preservation. Thirteen percent of patients received conformational technique and 87% received volumetric modulated arc therapy (VMAT). Radiotherapy delivered curative doses on the initial tumor/tumor bed of 60 and 66 Gy for operated patients and 70 Gy for non-operated patients, in fractions of 2 Gy to 2.12 Gy.
Of the 113 patients included, a total of 39 patients (35%) received the full treatment initially planned (induction chemotherapy followed by radiotherapy or radiochemotherapy) without cancellation or dose reduction. Causes for discontinuation of induction chemotherapy or dose reduction were varied: febrile aplasia, acute renal failure, grade ≥ 3 hand-foot syndrome, mucositis, vomiting, diarrhea, radiodermatitis, radiomucitis and death. No patients did not receive concomitant chemotherapy due to induction chemotherapy toxicity.

**TPF induction chemotherapy toxicities and predictive factors of toxicity**

TPF induction chemotherapy toxicities are described in Table 4. Predictive factors of these toxicities are described in Table 5.

### Table 1 Characteristics of 113 patients treated with TPF<sup>a</sup> induction chemotherapy for locally advanced head and neck cancer

|                   | Male sex – no. (%) | Average age [min-max] (years) | WHO Performance Index – no. (%) | Alcohol and tobacco use – no. (%) | Comorbidities – no. (%) | Tumor size – no. (%) |
|-------------------|--------------------|-------------------------------|--------------------------------|---------------------------------|------------------------|---------------------|
|                   | 89 (79)            | 58 [32–71]                    | 0                              | 56 (50)                         | Hepatic dysfunction    | T1                  |
|                   |                    |                               | 1                              | 52 (46)                         | Hepatic dysmorphism    | T2                  |
|                   |                    |                               | 2                              | 5 (4)                           | Diabetes               | T3                  |
|                   |                    |                               |                                |                                 | High blood pressure    | T4                  |
|                   |                    |                               |                                |                                 | Ischemic heart disease | Tx                  |
|                   |                    |                               |                                |                                 | Obliterative arteriopathy of the lower limbs | 3 (3)               |
|                   |                    |                               |                                |                                 | Obstructive pulmonary disease | 2 (2)               |
|                   |                    |                               |                                |                                 | Stroke                 | N0                  |
|                   |                    |                               |                                |                                 | Weight loss – median [min-max] (Kg) | 1                   |
|                   |                    |                               |                                |                                 | Serum Albumin – median [IC-95%] (g/l) | 1                   |
|                   |                    |                               |                                |                                 | Oral feeding possible at diagnosis – no. (%) | 1                   |
|                   |                    |                               |                                |                                 | Yes                    | 39.6 [37.6-39.8]    |
|                   |                    |                               |                                |                                 | No                     | 88 (78)             |
|                   |                    |                               |                                |                                 | Enteral nutrition during TPF – no. (%) | 25 (22)             |
|                   |                    |                               |                                |                                 | Yes                    | 34 (30)             |
|                   |                    |                               |                                |                                 | No                     | 79 (70)             |

<sup>a</sup>TPF docetaxel, cisplatin, 5-fluorouracil

Indication for laryngeal preservation vs. inoperable disease was not significantly correlated with the different TPF induction chemotherapy toxicities studied (see supplementary data Table S1).

### Hematotoxicity

14% grade ≥ 3 anemia, 6% grade ≥ 3 thrombocytopenia, 35% grade ≥ 3 neutropenia and 27% grade ≥ 3 febrile neutropenia were observed. In univariate analysis, female gender (<i>p</i> = 0.042), alcohol consumption (<i>p</i> = 0.02), pre-existing liver disease (<i>p</i> = 0.037) and a lowered prothrombin rate (<i>p</i> = 0.045) were correlated with an increased risk of grade ≥ 3 anemia. In univariate analysis, age (<i>p</i> = 0.039), pre-existing liver disease (<i>p</i> = 0.003), and liver dysmorphia on initial imaging (<i>p</i> = 0.027) were correlated with an increased risk of grade ≥ 3 thrombocytopenia. No predictive factors for grade ≥ 3 neutropenia or febrile neutropenia were found. In multivariate analysis, female gender (<i>p</i> = 0.039), alcohol consumption (<i>p</i> = 0.02), pre-existing liver disease (<i>p</i> = 0.037) and a lowered prothrombin rate (<i>p</i> = 0.045) were correlated with an increased risk of grade ≥ 3 anemia.
In univariate analysis, there was an increased risk of grade ≥ 3 anemia (\(p = 0.049\)) in patients with a lowered prothrombin rate.

**Other toxicities**

In univariate analysis, female gender was correlated with an increased risk of grade ≥ 3 nausea (\(p = 0.011\)) and grade ≥ 3 mucositis (\(p < 0.001\)) and a lowered prothrombin rate at diagnosis (\(< 80\%\)) was correlated with an increased risk of gastrointestinal bleeding (\(p = 0.03\)).

In multivariate analysis, there was an increased risk of infection (\(p = 0.047\)) in patients receiving enteral nutrition during induction chemotherapy. Thirty-six patients (32\%) developed an infection during induction chemotherapy.

**Deaths related to induction chemotherapy**

There were 6\% deaths (\(n = 7\)) during TPF induction chemotherapy (3/44 for laryngeal preservation patients, and 4/69 for inoperable patients). Five occurred after the first cycle. Four of them developed febrile neutropenia, one of which was complicated by colitis with gastrointestinal perforation. One patient presented a pneumopathy without neutropenia. One death occurred after the second cycle (sudden cardiopulmonary arrest at home) and another one after the third course (pneumonia in the context of febrile neutropenia). In univariate analysis, there was an increased risk of death related to induction chemotherapy was found in cases of liver disease (\(p = 0.032\)), a lowered prothrombin rate at diagnosis (\(< 80\%\)) (\(p = 0.021\)) or hepatic dysmorphia on initial imaging (\(p = 0.044\)). Neither sex, age, tumor stage, location, general condition, weight loss before or during TPF, nor enteral nutrition were significantly predictive of induction-chemotherapy-related death. In multivariate analysis, no factor was significantly correlated with the risk of death.

**TPF induction chemotherapy response rates**

Twenty-two percent of patients had a complete response after induction chemotherapy, 60\% had a partial response, 12\% had a stable disease, 5\% had continued progression, and 1\% had a discordant response in the primary tumour along with lymphadenopathy.

In univariate analysis, predictive factors of a better response (complete or partial response vs. stable or
progressive) were the possibility of oral feeding without a feeding tube ($p = 0.03$), higher albuminemia ($p = 0.006$), and weight loss < 5% at diagnosis ($p = 0.043$). In multivariate analysis, indication for inoperable disease was correlated with better response vs. laryngeal preservation ($p = 0.04$).

### Overall treatment response rates and survival data

The median follow-up was 48 months [0–103], in which 20% of patients had a recurrence (Table 3). Forty-two percent of patients ($n = 47$) were dead at last follow-up. Nine deaths were treatment-related (19%), 7 occurred during induction chemotherapy and 2 during radiotherapy. The median overall survival was 74 months and the median PFS was 20 months.

In multivariate analysis, the necessity of enteral feeding at diagnosis and a poor response (stable disease or progression) after induction chemotherapy were predictive of worse PFS ($p = 0.003$ and $p < 0.001$ respectively) and of worse OS ($p = 0.001$ and $p < 0.001$, respectively) (Fig. 1).

### Discussion

TPF induction chemotherapy used in the management of LAHNC has anti-tumor efficacy, with an overall response rate of 82% in our study and from 44 to 81% in

---

**Table 5** Predictive factors of toxicities of induction chemotherapy with TPF in patients treated for locally advanced head and neck cancer (multivariate analysis). Toxicity was assessed according to CTCAE classification V4.0

|                      | Anemia Grade ≥ 3 | Neutropenia Grade ≥ 3 | Febrile neutropenia Grade ≥ 3 | Infection | Death |
|----------------------|------------------|-----------------------|-------------------------------|-----------|-------|
| Age                  | NS               | NS                    | NS                            | NS        | NS    |
| Female sex           | NS               | NS                    | NS                            | NS        | NS    |
| Alcohol use          | NS               | NS                    | NS                            | NS        | NS    |
| Liver dysfunction    | NS               | NS                    | NS                            | NS        | NS    |
| Hepatic dysmorphia   | NS               | NS                    | NS                            | NS        | NS    |
| Prothrombin rate     | 0.049            | NS                    | NS                            | NS        | NS    |
| Diabetes             | NS               | NS                    | NS                            | NS        | NS    |
| HBP                  | NS               | NS                    | NS                            | NS        | NS    |
| Ischemic heart disease| NS              | NS                    | NS                            | NS        | NS    |
| Obstructive pulmonary disease | NS  | NS   | NS                | NS        | NS |
| Obliterative arteriopathy of the lower limbs | NS | NS | NS | NS | NS |
| Performance status   | NS               | NS                    | NS                            | NS        | NS    |
| Weight loss before TPF | NS            | NS                    | NS                            | NS        | NS    |
| Weight loss during TPF | NS          | NS                    | NS                            | NS        | NS    |
| Enteral feeding during TPF | NS          | NS                    | 0.047                          | NS        | NS    |

---

**Fig. 1** Overall survival of patients treated with TPF induction chemotherapy for locally advanced head and neck cancer based on response to induction chemotherapy
the literature for inoperable tumour [8, 20, 22, 23, 30] and about 80% for laryngeal preservation [18]. However, this induction protocol resulted in high rates of severe toxicities as well as a non-negligible rate of death.

The number of patients in our study remains relatively small (113 patients) but represents, to our knowledge, the largest “real life” trial published to date. This study is also retrospective, and thus represents a bias for the interpretation of the results. We included patients receiving TPF induction chemotherapy, either in a laryngeal preservation strategy or for inoperable LAHNC or locally advanced undifferenciated nasopharyngeal carcinoma. This population was therefore heterogeneous, but since the main endpoint of this study was TPF toxicity, this was not a major bias in the interpretation of the results, especially since we have not demonstrated significant differences in toxicities between patients receiving TPF as part of a laryngeal preservation protocol and those receiving TPF for an inoperable tumour. However, efficacy and survival data (secondary endpoints) in our study are to interpret with caution due to the heterogeneity of the population.

We showed that the introduction of an enteral feeding during induction chemotherapy increased the risk of infection ($p = 0.047$ in multivariate analysis). In addition, the prognosis of these patients appears to be generally worse. Indeed, the objective response, progression-free survival and overall survival rates were correlated with the possibility or not of oral feeding at diagnosis. Patients with head and neck cancer are at high risk of undernutrition due to previous alcohol and tobacco intoxication, but also due to impaired swallowing or limited mouth opening that may be caused by the tumor itself [34–36]. This risk may be increased by the mucosal and digestive toxicities specific to TPF. The infectious risks associated with enteral feeding can be of two types: firstly, there is a risk of pneumopathy, either by massive inhalation of nutrient solution or by repeated occult inhalation. Secondly, there is a risk of infection directly related to the placement of the gastrostomy. Our study suggests that patients whose nutritional status is such that they require enteral feeding are not good candidates for TPF induction therapy. Especially for patients with a laryngeal preservation strategy, radiochemotherapy may be more appropriate. However, there was no correlation between the markers of nutritional status used (albuminemia, weight loss) and toxicities, suggesting that these routinely used clinical and biological markers are insufficient. However, concerning albuminemia, our results are to be interpreted with caution since 25% of the data were missing, and in the absence of a systematic C-reactive protein (CRP) dosage. The search for other markers of nutritional status, particularly sarcopenia, would be interesting.

We found 6% iatrogenic deaths in patients receiving TPF induction chemotherapy for LAHNC, a rate similar to the ones found in the literature [8, 20–23, 30]. In our institution, for inoperable LAHNSCC, we reserve TPF induction chemotherapy for patients with rapidly evolving and/or highly symptomatic tumors with a large tumor burden. This is a population similar to that of the GORTEC 2007–02 trial with a death rate of 6.7% [30]. We found that the risk of death was increased in cases of pre-existing liver disease (alcoholic cirrhosis). Liver biology may be normal even in cases of proven cirrhosis and therefore does not by itself allow optimal patient selection. Patients diagnosed with hepatic cirrhosis are usually not treated with TPF, but retrospective analysis of the data from this patient cohort has allowed us to find, a posteriori, signs of cirrhosis prior to chemotherapy in some patients. The extension work-up for these head and neck cancers usually includes a cervico-thoracic CT scan more or less a PET scan for inoperable locally advanced tumors. Therefore, we do not always have at our disposal morphological liver imaging. The systematic performance of an abdominal CT scan or liver ultrasound could be discussed in order not to administer TPF chemotherapy to patients with hepatic dysmorphism.

An option for optimizing induction chemotherapy would be to lighten the chemotherapy regimen to decrease its toxicity, especially for inoperable LAHNC. The use of the modified TPF scheme [37] or the combination of docetaxel, cisplatin and cetuximab, which has achieved response rates of more than 50% [38] with an acceptable safety profile in relapsed or metastatic situations, could be an alternative to TPF. A combination of docetaxel, cisplatin, anti-PD-1 or anti-PD-L1 would also be worth comparing to TPF in terms of the efficacy and safety results of the combination of chemotherapy and anti-PD1 in relapsed or metastatic situations [39].

**Conclusions**

The role of TPF induction chemotherapy in the management of locally advanced head and neck cancers remains to be defined. As found in the literature, our study shows that TPF induction chemotherapy has a high objective response rate, but significant morbidity with 6% toxic deaths. Nutritional status and the presence of hepatic dysfunction (liver dysmophia on imaging or decrease prothrombin rate) seem to be the major elements to be taken into account in therapeutic decisions. Indeed, the need for enteral feeding at the beginning of treatment is associated with an increased risk of toxicities and poorer survival data. The presence of hepatic dysfunction is correlated with an increased risk of hematotoxicity grade ≥ 3 and an increased risk of death.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-08128-5.

Additional file 1: Table S1. Statistical analysis of toxicity profile differences between the laryngeal preservation group and inoperable disease group.

Acknowledgements

None.

Authors’ contributions

Guarantor of integrity of the entire study: MB, JB. Study concepts and design: MB, AFD, ML, JB. Literature research: MB, ML, MC, JB. Clinical studies: MB, ML, MC, JB. Experimental studies / data analysis: MB, AFD, JMi, JMo, NPD, NS, XD, JB, IM. Statistical analysis: IM. Manuscript preparation: MB, MC, JB. Experimental studies / data analysis: MB, AFD, JMi, JMo, NPD, NS, XD, JB. Literature research: MB, ML, MC, JB. Clinical studies: MB, ML, JB.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

Inquiries about datasets analyzed for this study can be directed to the corresponding author.

Declarations

Ethics approval and consent to participate

All methods were performed in accordance with the relevant guidelines and regulations. According the French legislation, the database has been declared to the French National Commission on Informatics and Liberty. Study ethics approval was obtained on 18 November 2020 from ethics committee “Comité d’Éthique des Centres d’Investigation Clinique CECIC Rhône-Alpes-Auvergne, Grenoble, IRB 5921”. According to the French legislation, and the ethics committee recommendations, all patients received a written informed consent about this study. They were free to oppose to the use of their personal data for this study by a non-opposition letter. According to the French legislation, and the ethics committee recommendations, and due to the retrospective nature of this study, a written consent from the patients was not necessary (only a non-opposition letter).

Consent for publication

Not applicable.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details

1 Medical Oncology Department, Jean PERRIN Center, 63011 Clermont-Ferrand, France. 2 Clinical Research Division, Delegation for Clinical Research and Innovation, Jean PERRIN Center, 63011 Clermont-Ferrand, France. 3 Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France. 4 Radiotherapy department, Centre de lutte contre le cancer Jean PERRIN, 58 Rue Montalembert, 63011 Clermont-Ferrand, France. 5 Center Clermont-Ferrand, 63000 Clermont-Ferrand, France. 6 Department of Maxillofacial and Plastic Surgery, Esata University Hospital Center Clermont-Ferrand, 63000 Clermont-Ferrand, France. 7 Department of Otorhinolaryngology - Head and Neck Surgery, Gabriel Montpied University Hospital Center, 63000 Clermont-Ferrand, France.

Received: 5 January 2021 Accepted: 23 March 2021

References

1. Schwanzinger M, Huguet F, Térmann S, Pointreau Y, Bec M, Even C, et al. PO-120: head and neck cancers are associated with poor EQ-SD-related utility in France (EPCORL study). Radiother Oncol. 2017;122:57. https://doi.org/10.1016/j.radonc.2017.03.024.

2. Hawkins NV. Panel discussion on glottic tumors. VIII. The treatment of glottic carcinoma: an analysis of 800 cases. Laryngoscope. 2009;85(9): 1485–93.

3. Jesse RH. The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. Laryngoscope. 1975;85(9):1424–9. https://doi.org/10.1288/00005537-197509000-00002.

4. Harwood AR, Ravilinson E. The quality of life of patients following treatment for laryngeal cancer. Int J Radiat Oncol Biol Phys. 1985;9(3):335–8. https://doi.org/10.1016/0360-3016(85)90229-4.

5. McNeil BJ, Weichselbaum RR, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981;305(17):982–7. https://doi.org/10.1056/NEJM198110223051704.

6. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685–90.

7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78. https://doi.org/10.1056/NEJMoa053422.

8. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and Docetaxel in Unresectable head and neck Cancer. N Engl J Med. 2007;357(17):1695–704. https://doi.org/10.1056/NEJMoa071028.

9. Posner MR, Hershock DM, Blajciewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with Docetaxel in head and neck Cancer. N Engl J Med. 2007;357(17):1705–15. https://doi.org/10.1056/NEJMoa070956.

10. Pignon JP, le Naire A, Maillet E, Bourhis J. MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009;92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014.

11. Blanchard P, Bourhis J, Lucas B, Posner MR, Vermorken JB, Hernandez JJC, et al. Taxane-Cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck Cancer group. J Clin Oncol. 2013;31(23):2854–60. https://doi.org/10.1200/JCO.2012.47.7802.

12. Pignon JP, Bourhis J, Dominge C, Design C. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck Cancer. Lancet Lond Engl. 2000;355(9196):949–55. https://doi.org/10.1016/S0140-6736(00)07011-4.

13. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KH, Winquist EW, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20(5):921–7. https://doi.org/10.1093/a ronc/mdn752.

14. Blanchard P, Baujat B, Holostenco V, Bourjelmaj A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;100(1):33–40. https://doi.org/10.1016/j.radonc.2010.05.036.

15. Richard JM, Sanchez-Garner H, Pessey JJ, Loubois B, Lefebvre JL, Dehesdin D, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34(3):224–8. https://doi.org/10.1016/S1368-8375(97)00090-0.

16. Forastiere AA, Gooptet H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal Cancer. N Engl J Med. 2003;349(22):2091–8. https://doi.org/10.1056/NEJMoa031317.
17. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, et al. Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. J Natl Cancer Inst. 2009; Available from: http://jnci journa/nci/content/early/2009/01/17/jnci. dj4460. [cited 2016 Feb 7].

18. Lefebvre JL, Andy G, Chevalier D, Luboinski B, Collette L, Trissard LC, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23(10):2708–14. https://doi.org/10.1093/annonc/mdq065.

19. Pointreau Y, Garaud P, Chatelot S, Siré C, Tuchais C, Tortalou X, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498–506. https://doi.org/10.1093/jnci/djp007.

20. Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol. 2010;21(1):151–9. https://doi.org/10.1093/annonc/mdp573.

21. Haddad R, O'Neill A, Rabinowits G, Tisher R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–64. https://doi.org/10.1016/S1470-2045(13)70011-1.

22. Hitt R, Grav JL, López-Pousa A, Bernocal A, García-Girón C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(1):216–25. https://doi.org/10.1093/annonc/mdt461.

23. Takács-Nagy Z, Hitte E, Remenár E, Öbema F, Polgár C, Major T, et al. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III–IV unresectable head and neck cancer. Strahlenther Onkol. 2015;191(8):635–41. https://doi.org/10.1002/str.20829.

24. Budach W, Böle E, Kammers K, Gerber PA, Orth K, Gripp S, et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;118(3):270–83. https://doi.org/10.1007/s00066-015-0829-z.

25. Geoffrois L, Martin L, De Raucourt D, Sun XS, Tso Y, Maingon P, et al. Induction chemotherapy followed by Cetuximab radiotherapy is not superior to concurrent Chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(31):3077–83. https://doi.org/10.1200/JCO.2017.76.2591.

26. Geofrois L, Martin L, De Raucourt D, Sun XS, Tso Y, Maingon P, et al. Induction chemotherapy followed by Cetuximab radiotherapy is not superior to concurrent Chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2013;31(17):2060–9. https://doi.org/10.1200/JCO.2012.42.9888.

27. Geoffrois L, Martin L, De Raucourt D, Sun XS, Tso Y, Maingon P, et al. Induction docetaxel platinum S-FU (TPF) followed by cetuximab-radiotherapy (ceux-RT) versus concurrent chemoradiotherapy (CT-RT) in patients with N2b-c/N3 non operated stage III–IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007–02 phase III randomized trial. J Clin Oncol. 2016;34(15_suppl):6000.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more @biomedcentral.com/submissions